Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries including France, Italy, Belgium, and the Netherlands.

The company reported successful contracts for the anticancer biosimilars Herzuma (trastuzumab) for breast and stomach cancer treatment and Vegzelma (bevacizumab) for non-small cell lung cancer and metastatic colorectal cancer therapy from public hospital unions GRAPS and GAULoYS in France.

Additionally, Vegzelma was awarded in the GRECAPS, Groupement Niort, and Groupement PharmSERA bids.

Depending on the deals with specific institutions, these products will be supplied to the five public hospital unions for the next two to four years. The company explained that these hospital unions hold approximately 10% of the French anticancer drug market.

In Italy, the anticancer biosimilars Truxima (rituximab) and Herzuma and Vegzelma were successfully contracted in government tenders by Friuli-Venezia Giulia and Sicilia regions.

The products will be supplied for two years to Sicilia and four years and six months to Friuli-Venezia Giulia.

Furthermore, in the Hospilim bid for Belgium's Limburg region hospital union, Herzuma and Vegzelma were successful, and they will be supplied for four years.

Additionally, Celltrion won a bid from Santeon, the top-seven hospital union in the Netherlands, for Truxima and Herzuma, with the products set to be supplied for two years starting this month.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com